Last updated: 2026-09-09 04:30:01. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioVie, Inc. (BIVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.07, with a market capitalization of $16.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.82 to $3.79. This page covers its latest market performance, valuation, price trends and company information.
$16.90M | |
$2.06 | |
$4,609.77 | |
$0.82 | |
$2.00 | |
312.68K | |
4.62M | |
-- | |
$3.79 | |
$0.82 | |
-- | |
-- |
BioVie, Inc. (BIVI) last closed at $2.00 as of 2026-09-08 22:42:00, unchanged from the previous close of $2.00.
During the latest regular trading session, BIVI traded between $0.82 and $4,609.77, with a volume of 312.68K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, BioVie, Inc. (BIVI) moved from $2.19 to $2.07, representing a decline of 5.71% ($0.13).
The stock traded between $1.96 and $2.49 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 622.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 41.9%
BIVI is currently trading at $2.07, placing it 41.9% of the way from its 52-week low of $0.82 to its 52-week high of $3.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioVie, Inc. (BIVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.